AbbVie presented new data from its novel antibody-drug conjugates (ADCs) at ASCO 2025, including telisotuzumab adizutecan in advanced non-small cell lung cancer, ABBV-706 in high-grade neuroendocrine ...

Going into 2025, we expect pharma brands and their advertising partners to use past learnings – and, more importantly – ...

Changing a cultural undertow is one of the hardest leadership challenges in any industry, and perhaps even more so in the ...

UK start-up George Medicines has brought its triple therapy for high blood pressure over the finish line, with an FDA ...

Clesrovimab has been held up by MSD (known as Merck & Co in the US and Canada) as offering simpler dosing and better clinical ...

Novo Nordisk's GLP-1 agonist semaglutide, used to treat diabetes and obesity, may cause a serious eye condition that can lead ...

The NHS is reported to be in line for a £30 billion ($40.7 billion) increase to its budget in the UK government's upcoming ...

Otsuka and Vera Therapeutics have both presented new data on drug candidates for IgA nephropathy (IgAN), striving to join a ...

Threshold Pharma is to go ahead with Phase 3 clinical trials of its only drug, TH-302, despite recent Phase 2 trials failing to show statistically significant improvement in overall survival.

COP27 is in full swing and world leaders are contending with the fact that we will likely not meet the Paris Agreement’s 1.5°C target. The reality is that we will need to focus on limiting a ...

There’s a common public perception of pharma executives as callous, money-hungry suits who want as many people to be sick as possible – so they’ll pay as much as possible for their drugs.

Patient flow forecasting is a fundamental tool in healthcare and pharmaceutical industries, enabling stakeholders to predict and plan for the treatment requirements of patients accurately.